Condition: Chronic Hepatitis D · Sponsor: Mirum Pharmaceuticals, Inc.
This is a Phase 2b/3, randomized, open-label, multicenter trial evaluating the efficacy and safety of switching from bulevirtide to brelovitug for the treatment of chronic hepatitis Delta infection (CHD).
This description comes directly from the study's public registry record.
Clinical Trials Mirum · +16506674085 · clinicaltrials@mirumpharma.com
Medinfo Mirum · medinfo@mirumpharma.com
Always discuss trial participation with your own doctor first.
| Medical University of Graz | Graz, Austria | Recruiting |
| Medizinische Universitat Innsbruck | Innsbruck, Austria | Recruiting |
| Fakultni Nemocnice Brno (University Hospital Brno) | Brno, Czechia | Recruiting |
| Klin Med Ltd. (KLIN MED s.r.o.) | Prague, Czechia | Recruiting |
| Institut klinicke a experimentalni mediciny- IKEM (Institute for Clinical and Experimental Medicine) | Prague, Czechia | Recruiting |
| CHU de Bordeaux | Bordeaux, France | Recruiting |
| Clermont-Ferrand University Hospital | Clermont-Ferrand, France | Recruiting |
| Hospital Beaujon | Clichy, France | Recruiting |
| Henri Mondor University Hospital (APHP) | Créteil, France | Recruiting |
| CHU Grenoble Alpes Hopital Nord Michallon | Grenoble, France | Recruiting |
| CHU Limoges | Limoges, France | Recruiting |
| Hospital De La Croix Rousse | Lyon, France | Recruiting |
+ 23 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07454837